Patents by Inventor Francis Hung Nguyen

Francis Hung Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants of vascular endothelial cell growth factor, their uses, and processes for their production
    Patent number: 7427596
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect of binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: September 23, 2008
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara
  • Variants of vascular endothelial cell growth factor
    Patent number: 7005505
    Abstract: The present invention involves the preparation of vascular endothelial growth actor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: February 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara
  • Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
    Publication number: 20040152636
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) antagonist molecules comprising variant VEGF polypeptides which are capable of binding to and occupying cell surface VEGF receptors without inducing a VEGF response, thereby antagonizing the biological activity of the native VEGF protein. Specifically, the variant VEGF polypeptides of the present invention comprise modifications of at least one cysteine residue in the native VEGF sequence, thereby inhibiting the ability of the variant polypeptide to dimerize through the formation of disulfide bonds. The present invention is further directed to methods for preparing such variant VEGF antagonists and to methods, compositions and assays utilizing such variants for producing pharmaceutically active materials having therapeutic and pharmacologic properties that differ from the native VEGF protein.
    Type: Application
    Filed: March 3, 2004
    Publication date: August 5, 2004
    Applicant: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara
  • Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
    Patent number: 6750044
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) antagonist molecules comprising variant VEGF polypeptides which are capable of binding to and occupying cell surface VEGF receptors without inducing a VEGF response, thereby antagonizing the biological activity of the native VEGF protein. Specifically, the variant VEGF polypeptides of the present invention comprise modifications of at least one cysteine residue in the native VEGF sequence, thereby inhibiting the ability of the variant polypeptide to dimerize through the formation of disulfide bonds. The present invention is further directed to methods for preparing such variant VEGF antagonists and to methods, compositions and assays utilizing such variants for producing pharmaceutically active materials having therapeutic and pharmacologic properties that differ from the native VEGF protein.
    Type: Grant
    Filed: October 17, 1996
    Date of Patent: June 15, 2004
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara
  • Variants of vascular endothelial cell growth factor
    Patent number: 6057428
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: May 2, 2000
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara, Brian C. Cunningham, James A. Wells, Bing Li
  • Nucleic acids encoding variants of vascular endothelial cell growth factor
    Patent number: 6020473
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: February 1, 2000
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara